CSPC Pharmaceutical Group has been granted a patent for a pharmaceutical composition targeting Cx43 hemichannels in astrocytes or osteocytes to treat inflammatory or neurodegenerative diseases like spinal cord injury. The formulation includes an anti-Cx43 antibody with specific amino acid sequences. GlobalData’s report on CSPC Pharmaceutical Group gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on CSPC Pharmaceutical Group, Anti-bacterial thiazole derivatives was a key innovation area identified from patents. CSPC Pharmaceutical Group's grant share as of February 2024 was 51%. Grant share is based on the ratio of number of grants to total number of patents.
Pharmaceutical formulation for treating inflammatory or neurodegenerative diseases
See Also:
A recently granted patent (Publication Number: US11912764B2) discloses a pharmaceutical formulation designed to inhibit the opening of Cx43 hemichannels in cells, with potential applications in treating inflammatory or neurodegenerative diseases. The formulation includes an anti-Cx43 antibody or antigen binding fragment, a buffer (such as histidine/aspartic acid), a surfactant (polysorbate 80), and a stabilizer (like sucrose), all combined to achieve a pH range of 5 to 6. The antibody component comprises specific heavy and light chain complementarity determining region (CDR) sequences, with defined amino acid sequences, ensuring targeted binding to an epitope within the FLSRPTEKTI amino acid sequence.
Moreover, the patent details specific concentrations and components of the formulation, such as the anti-Cx43 antibody at 50 mg/mL, the buffer composition, surfactant, and stabilizer choices, all contributing to the formulation's efficacy. The pH range of 5.4 to 5.6, along with the aqueous nature of the formulation, further enhances its stability and bioavailability. Additionally, the patent includes a method claim for administering the formulation to inhibit Cx43 hemichannel opening, emphasizing its therapeutic potential for inflammatory and neurodegenerative conditions. The precise composition and characteristics outlined in the patent aim to optimize the formulation's effectiveness in targeting Cx43 hemichannels, showcasing a novel approach in pharmaceutical development for treating specific diseases.
To know more about GlobalData’s detailed insights on CSPC Pharmaceutical Group, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
